

March 16, 2012

Termination and Cash Distribution

Name: Crucell N.V.
DR CUSIP: 228769105
DR ISIN: US2287691057
DR Ticker Symbol: CRLXY
Ratio (DRs:Underlying Shares): 1:1

BNY Mellon has been advised that Crucell N.V. has been compulsorily acquired by way of a public offer by JJC Acquisition Company B.V. ("JJC"), a subsidiary of Johnson & Johnson for all issued and outstanding capital of Crucell. As a result, for each Crucell N.V. Ordinary Share, BNY Mellon received EUR 24.75 plus statutory interest of EUR 0.0461 in cash at its custodian banks in Netherlands.

The cash consideration from the acquisition will be distributed to Owners and Beneficial Owners of American Depositary Receipts ("ADRs"), representing American Depositary Shares ("ADSs") on a pro-rata basis. As a result of the compulsory acquisition of Crucell N.V. by JJC, the Deposit Agreement is deemed to be terminated.

Please be advised beginning March 22, 2012, Owners of Crucell N.V. Limited ADRs will be required on a mandatory basis to surrender their ADRs to BNY Mellon for cancellation and exchange for the cash consideration received from Crucell N.V. calculated as follows:

Gross Rate per ADS:	\$32.480411
Cancellation Fee:	<u>\$0.050000</u>
Net Rate per ADS:	\$32.430411

The books are closed for all transactions.

To learn more about Depositary Receipts and issuer programs, please contact our marketing desks:

<i>New York</i>	<i>London</i>	<i>Hong Kong</i>
Ravi Davis	Damon Rowan	Joe Oakenfold
Vice President	Vice President	Vice President
+1 212 815-4245	+44 207 964 6527	+852 2 840 9717
Ravi.davis@bnymellon.com	damon.rowan@bnymellon.com	joe.oakenfold@bnymellon.com

BNY Mellon may pay a rebate to brokers in connection with the deposit of shares for the issuance of unsponsored DRs; broker may or may not disclose or pass back some or all of such rebate to the DR investor. BNY Mellon may also transact with affiliate brokers and dealers.

This information and data is provided for general purposes only; it is not investment advice and should not be used for any investment decisions nor trading purposes. BNY Mellon does not warrant or guarantee the accuracy, timeliness or completeness of this announcement and shall have no liability for investment or other decisions based hereon, including market values loss on the sales or purchase of securities or other instruments or obligations. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.